Medpace downgraded to Neutral from Outperform at Baird
Baird analyst Eric Coldwell downgraded Medpace to Neutral from Outperform with a price target of $547, up from $477. not While "not worried" about 2026 guidance, the analyst says the stock "is a Yo-Yo and day-of-reporting up/down trades are utter madness." The firm's downgrade is more about near-term uncertainty and re